Capsule Summary Slidesets

Share

Program Content

Activities

  • CHRYSALIS: Ami for <i>MET</i>ex14+ NSCLC
    CHRYSALIS: Updated Phase I Trial Results of Amivantamab in Advanced NSCLC With MET Exon 14 Skipping Mutations
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2022

    Expires: June 09, 2023

  • NADIM II: Neoadj Nivo + CT
    NADIM II: Phase II Trial of Neoadjuvant Nivolumab + Chemotherapy vs Chemotherapy in Resectable Stage IIIA/B NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2022

    Expires: June 09, 2023

  • ATLANTIS Lurbinectedin Monotherapy
    ATLANTIS: Analysis of Outcomes With Single-Agent Lurbinectedin After Lurbinectedin + Doxorubicin in Relapsed SCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2022

    Expires: June 07, 2023

  • KRYSTAL-1
    KRYSTAL-1 Trial of Adagrasib in Patients With Previously Treated Advanced KRASG12C-Mutated NSCLC: Analysis of Registrational Phase II Cohort
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2022

    Expires: June 05, 2023

  • TACTI-002
    Phase II TACTI-002 Trial: Updated Results With Eftilagimod Alpha Plus Pembrolizumab as First-line Therapy in Advanced NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2022

    Expires: June 06, 2023

  • CHRYSALIS-2 Update
    CHRYSALIS-2: Update of Amivantamab + Lazertinib in EGFR-Mutant NSCLC After Progression on Osimertinib and Chemotherapy
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2022

    Expires: June 13, 2023

  • CLN-081: <i>EGFR</i> ex20ins+ NSCLC
    Updated Results of a Phase I/IIa Trial of CLN-081, a Selective EGFR TKI, in Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2022

    Expires: June 09, 2023

  • ATEZO-BRAIN Update
    Phase II ATEZO-BRAIN: Updated Results With Atezolizumab + Carboplatin/Pemetrexed in Advanced Nonsquamous NSCLC With Untreated Brain Metastases
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 16, 2022

    Expires: June 15, 2023

  • Patritumab Deruxtecan in Adv NSCLC
    Phase I Trial of Patritumab Deruxtecan for Previously Treated Advanced NSCLC Without EGFR Activating Mutations
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

  • OPAL: 1L Osi + CT in NSCLC
    OPAL: Phase II Trial of First-line Osimertinib Plus Platinum-Based Doublet Chemotherapy in EGFR-Mutated Advanced NSCLC
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

  • SKYSCRAPER-02
    SKYSCRAPER-02: Phase III Trial of First-line Atezolizumab + Carboplatin/Etoposide ± Tiragolumab, an Anti-TIGIT Antibody, in ES-SCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

  • CheckMate 816 Post Hoc EFS Analysis
    CheckMate 816: Association of Pathologic Regression With EFS for Neoadjuvant Nivolumab + CT in Resectable NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2022

    Expires: June 09, 2023

  • KRYSTAL-1 CNS Cohort
    KRYSTAL-1: Phase Ib Report of Adagrasib Activity in Patients With KRAS G12C–Mutated NSCLC and Active, Untreated CNS Metastases
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 13, 2022

    Expires: June 12, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab